Search MAVA.org:

Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email mava@mava.org.

Check back regularly for news, coverage, and announcements about MAVA.

New Enterprise Associates Joins $28 Million In Series B For Cardioxyl Pharmaceuticals

11/13/2012

Cardioxyl Pharmaceuticals, Inc. announced that it has raised $28 million in a Series B financing led by OrbiMed Advisors. New investor Osage University Partners joined OrbiMed and returning investors New Enterprise Associates (NEA) and The Aurora Funds in the financing. Proceeds from this latest round will be used to further advance Cardioxyl's second-generation nitroxyl (HNO) donor programs for the treatment of acute and chronic heart failure.